Krystal Biotech Inc

1KRYS

Company Profile

  • Business description

    Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

  • Contact

    2100 Wharton Street
    Suite 701
    PittsburghPA15203
    USA

    T: +1 412 586-5830

    E: [email protected]

    https://www.krystalbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    275

Stocks News & Analysis

stocks

Ask the analyst: Are Qantas shares a value trap?

Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks

Palantir earnings: Blockbuster growth amid high expectations

We raise our fair value estimate off the back of earnings.
stocks

ResMed earnings: Solid showing from ASX healthcare winner

Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,111.1082.300.91%
CAC 407,661.1640.120.53%
DAX 4023,973.66127.590.54%
Dow JONES (US)44,111.7461.90-0.14%
FTSE 1009,160.1717.440.19%
HKSE24,958.3055.770.22%
NASDAQ20,916.55137.03-0.65%
Nikkei 22540,794.86245.320.60%
NZX 50 Index12,880.163.120.02%
S&P 5006,299.1930.75-0.49%
S&P/ASX 2008,843.7073.300.84%
SSE Composite Index3,633.9916.400.45%

Market Movers